Failure for Tarceva plus Nexavar in HCC after no survival benefit shown over Nexavar alone
This article was originally published in Scrip
Executive Summary
Astellas/Roche's Tarceva (erlotinib) when added to Bayer/Onyx Pharmaceuticals' Nexavar (sorafenib) did not improve overall survival compared with Nexavar alone in patients with unresectable hepatocellular carcinoma (HCC).